Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Beam Therapeutics

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces Transition of Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in Upcoming September Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in Upcoming May Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.